Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib as Neoadjuvant Therapy for Localized Prostate Cancer
NCT03570476Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Sep 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in prostate cancer (PCa), sponsored by University of Washington. Started Sep 2018; status: terminated.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03570476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570476.